Contrast-Enhanced Magnetic Resonance Angiography in Rats with Gadobenate Dimeglumine at 3T
This study aimed to investigate the magnetic resonance
(MR) signal enhancement ratio (ER) of contrast-enhanced MR
angiography (CE-MRA) in normal rats with gadobenate dimeglumine
(Gd-BOPTA) using a clinical 3T scanner and an extremity coil. The
relaxivities of Gd-BOPTA with saline only and with 4.5% human
serum albumin (HSA) were also measured. Compared with
Gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA),
Gd-BOPTA had higher relaxivities. The maximum ER of aorta (ERa),
kidney, liver and muscle with Gd-BOPTA were higher than those with
Gd-DTPA. The maximum ERa appeared at 1.2 min and decayed to half
at 10 min after Gd-BOPTA injection. This information is helpful for
the design of CE-MRA study of rats.
[1] A. Levent, I. Yuce, S. Eren, O. Ozyigit, and M. Kantarci,
“Contrast-Enhanced and Time-of-Flight MR Angiographic Assessment
of Endovascular Coiled Intracranial Aneurysms at 1.5 T,” Interv
Neuroradiol., vol. 20, pp. 686-92, Dec 2014.
[2] S. Roujol, M. Foppa, T.A. Basha, M. Akçakaya, K.V. Kissinger, B.
Goddu, S. Berg, and R. Nezafat, “Accelerated free breathing ECG
triggered contrast enhanced pulmonary vein magnetic resonance
angiography using compressed sensing,” J Cardiovasc Magn Reson., vol.
16, pp. 91, Nov 2014.
[3] S. Mavrogeni, G. Markousis-Mavrogenis, and G. Kolovou, “Contribution
of cardiovascular magnetic resonance in the evaluation of coronary
arteries,” World J Cardiol., vol. 6, pp. 1060-6, Oct 2014.
[4] X. Mu, H. Wang, Q. Ma, C. Wu, and L. Ma, “Contrast-enhanced
magnetic resonance angiography for the preoperative evaluation of
hepatic vascular anatomy in living liver donors: a meta-analysis,” Acad
Radiol., vol. 21, pp. 743-9, Jun 2014.
[5] A. M. Saindane, S. R. Boddu, F. C. Tong, S. Dehkharghani, and J. E. Dion,
“Contrast-enhanced time-resolved MRA for pre-angiographic evaluation
of suspected spinal dural arterial venous fistulas,” J Neurointerv Surg.,
vol. 7, pp. 135-40, Feb. 2015.
[6] H. P. Niendorf, J. C. Dinger, J. Haustein, I. Cornelius, A. Alhassan, W.
Clauss, “Tolerance data of Gd-DTPA: a review,”Eur J Radiol., Vol. 13,
pp. 15-21, Jul-Aug 1991.
[7] M. A. Kirchin, G. P. Pirovano, A. Spinazzi, “Gadobenatedimeglumine
(Gd-BOPTA). An overview,” Invest Radiol., Vol. 33, pp. 798-809, Nov.
1998.
[8] K. Yoshikawa, Y. Inoue, M. Shimada, M. Akahane, S. Itoh, A. Seno, S.
Hayashi., “Contrast-enhanced MRangiography in rats with hepatobiliary
contrast agents,”Magn Reson Imaging., Vol. 22, pp. 937-42, Sep. 2004.
[9] E. M. Haacke, R. W. Brwon, M. R. Thompson, R. Venkatesan, Magnetic
Resonance Imaging: Physical Principles and Sequence Design, New
York, NY: John Wiley and Sons Inc, 1999, pp. 128.
[10] J. C. Jao, H.C. Lu, H. Y. Lu, Y. M. Wang, G.C. Liu, L. M. Lin, P. Y. Chu,
S..H. Chen, P. C. Chen, “The Imaging Behavior of an MRI Contrast
Agent (Gd(TTDA-BOM)2- in a Mice Liver Model at 3 Tesla,” J Med Biol
Eng., Vol. 30, pp. 139-144, Jun 2010.
[11] X. Xing, X. Zeng, X. Li, Q. Zhao, M.A. Kirchin, G. Pirovano, X. Wang,
Y. Li, R. Iezzi, and F. De Cobelli, “Contrast-enhanced MR angiography:
does a higher relaxivity MR contrast agent permit a reduction of the dose
administered for routine vascular imaging applications?,”Radiol Med.,
vol. 120, pp. 239-50, Feb 2015.
[12] K.L. Nguyen, S.N. Khan, J.M. Moriarty, K. Mohajer, P. Renella, G.
Satou, I. Ayad, S. Patel, M.I. Boechat, and J.P. Finn, “High-field MR
imaging in pediatric congenital heart disease: initial results,”
PediatrRadiol., vol. 45(1), pp. 42-54, Jan 2015.
[13] S. Gaddikeri, L. Mitsumori, S. Vaidya, D.S. Hippe, P. Bhargava, and
M.K. Dighe, “Comparing the diagnostic accuracy of contrast-enhanced
computed tomographic angiography and gadolinium-enhancedmagnetic
resonance angiography for the assessment of hemodynamically
significant transplant renal artery stenosis,” CurrProblDiagnRadiol., vol.
43, pp. 162-8, Jul. 2014.
[1] A. Levent, I. Yuce, S. Eren, O. Ozyigit, and M. Kantarci,
“Contrast-Enhanced and Time-of-Flight MR Angiographic Assessment
of Endovascular Coiled Intracranial Aneurysms at 1.5 T,” Interv
Neuroradiol., vol. 20, pp. 686-92, Dec 2014.
[2] S. Roujol, M. Foppa, T.A. Basha, M. Akçakaya, K.V. Kissinger, B.
Goddu, S. Berg, and R. Nezafat, “Accelerated free breathing ECG
triggered contrast enhanced pulmonary vein magnetic resonance
angiography using compressed sensing,” J Cardiovasc Magn Reson., vol.
16, pp. 91, Nov 2014.
[3] S. Mavrogeni, G. Markousis-Mavrogenis, and G. Kolovou, “Contribution
of cardiovascular magnetic resonance in the evaluation of coronary
arteries,” World J Cardiol., vol. 6, pp. 1060-6, Oct 2014.
[4] X. Mu, H. Wang, Q. Ma, C. Wu, and L. Ma, “Contrast-enhanced
magnetic resonance angiography for the preoperative evaluation of
hepatic vascular anatomy in living liver donors: a meta-analysis,” Acad
Radiol., vol. 21, pp. 743-9, Jun 2014.
[5] A. M. Saindane, S. R. Boddu, F. C. Tong, S. Dehkharghani, and J. E. Dion,
“Contrast-enhanced time-resolved MRA for pre-angiographic evaluation
of suspected spinal dural arterial venous fistulas,” J Neurointerv Surg.,
vol. 7, pp. 135-40, Feb. 2015.
[6] H. P. Niendorf, J. C. Dinger, J. Haustein, I. Cornelius, A. Alhassan, W.
Clauss, “Tolerance data of Gd-DTPA: a review,”Eur J Radiol., Vol. 13,
pp. 15-21, Jul-Aug 1991.
[7] M. A. Kirchin, G. P. Pirovano, A. Spinazzi, “Gadobenatedimeglumine
(Gd-BOPTA). An overview,” Invest Radiol., Vol. 33, pp. 798-809, Nov.
1998.
[8] K. Yoshikawa, Y. Inoue, M. Shimada, M. Akahane, S. Itoh, A. Seno, S.
Hayashi., “Contrast-enhanced MRangiography in rats with hepatobiliary
contrast agents,”Magn Reson Imaging., Vol. 22, pp. 937-42, Sep. 2004.
[9] E. M. Haacke, R. W. Brwon, M. R. Thompson, R. Venkatesan, Magnetic
Resonance Imaging: Physical Principles and Sequence Design, New
York, NY: John Wiley and Sons Inc, 1999, pp. 128.
[10] J. C. Jao, H.C. Lu, H. Y. Lu, Y. M. Wang, G.C. Liu, L. M. Lin, P. Y. Chu,
S..H. Chen, P. C. Chen, “The Imaging Behavior of an MRI Contrast
Agent (Gd(TTDA-BOM)2- in a Mice Liver Model at 3 Tesla,” J Med Biol
Eng., Vol. 30, pp. 139-144, Jun 2010.
[11] X. Xing, X. Zeng, X. Li, Q. Zhao, M.A. Kirchin, G. Pirovano, X. Wang,
Y. Li, R. Iezzi, and F. De Cobelli, “Contrast-enhanced MR angiography:
does a higher relaxivity MR contrast agent permit a reduction of the dose
administered for routine vascular imaging applications?,”Radiol Med.,
vol. 120, pp. 239-50, Feb 2015.
[12] K.L. Nguyen, S.N. Khan, J.M. Moriarty, K. Mohajer, P. Renella, G.
Satou, I. Ayad, S. Patel, M.I. Boechat, and J.P. Finn, “High-field MR
imaging in pediatric congenital heart disease: initial results,”
PediatrRadiol., vol. 45(1), pp. 42-54, Jan 2015.
[13] S. Gaddikeri, L. Mitsumori, S. Vaidya, D.S. Hippe, P. Bhargava, and
M.K. Dighe, “Comparing the diagnostic accuracy of contrast-enhanced
computed tomographic angiography and gadolinium-enhancedmagnetic
resonance angiography for the assessment of hemodynamically
significant transplant renal artery stenosis,” CurrProblDiagnRadiol., vol.
43, pp. 162-8, Jul. 2014.
@article{"International Journal of Biological, Life and Agricultural Sciences:70070", author = "Jo-Chi Jao and Yen-Ku Chen and Twei-Shiun Jaw and Po-Chou Chen", title = "Contrast-Enhanced Magnetic Resonance Angiography in Rats with Gadobenate Dimeglumine at 3T", abstract = "This study aimed to investigate the magnetic resonance
(MR) signal enhancement ratio (ER) of contrast-enhanced MR
angiography (CE-MRA) in normal rats with gadobenate dimeglumine
(Gd-BOPTA) using a clinical 3T scanner and an extremity coil. The
relaxivities of Gd-BOPTA with saline only and with 4.5% human
serum albumin (HSA) were also measured. Compared with
Gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA),
Gd-BOPTA had higher relaxivities. The maximum ER of aorta (ERa),
kidney, liver and muscle with Gd-BOPTA were higher than those with
Gd-DTPA. The maximum ERa appeared at 1.2 min and decayed to half
at 10 min after Gd-BOPTA injection. This information is helpful for
the design of CE-MRA study of rats.", keywords = "Contrast-Enhanced Magnetic Resonance
Angiography, Gd-BOPTA, Gd-DTPA, Rat.", volume = "9", number = "6", pages = "621-4", }
